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Abstract
Purpose—Nanoparticle technology represents an attractive approach for formulating poorly 
water soluble pulmonary medicines. Unfortunately, nanoparticle suspensions used in nebulizers or 
metered dose inhalers often suffer from physical instability in the form of uncontrolled 
agglomeration or Ostwald ripening. In addition, processing such suspensions into dry powders can 
yield broad particle size distributions. To address these encumbrances, a controlled nanoparticle 
flocculation process has been developed.
Method—Nanosuspensions of the poorly water soluble drug budesonide were prepared by 
dissolving the drug in organic solvent containing surfactants followed by rapid solvent extraction 
in water. Different surfactants were employed to control the size and surface charge of the 
precipitated nanoparticles. Nanosuspensions were flocculated using leucine and lyophilized.
Results—Selected budesonide nanoparticle suspensions exhibited an average particle size 
ranging from ~160–230 nm, high yield and high drug content. Flocculated nanosuspensions 
produced micron-sized agglomerates. Freeze-drying the nanoparticle agglomerates yielded dry 
powders with desirable aerodynamic properties for inhalation therapy. In addition, the dissolution 
rates of dried nanoparticle agglomerate formulations were significantly faster than that of stock 
budesonide.
Conclusion—The results of this study suggest that nanoparticle agglomerates possess the 
microstructure desired for lung deposition and the nanostructure to facilitate rapid dissolution of 
poorly water soluble drugs.
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1. Introduction
Pulmonary dosage forms have established an important role in the local treatment of lung 
diseases. Systemic treatments delivered through the lungs are also emerging since this route 
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offers access to a well blood-supplied surface area, avoids first-pass metabolism, and 
reduces drug degradation that may occur in the gastrointestinal tract (1, 2). Pulmonary drug 
delivery approaches continue to develop rapidly in an effort to improve product stability and 
efficacy for local and systemic treatment of diseases (3, 4). One problem with pulmonary 
drug delivery is the poor deposition efficiency as, in some cases, only approximately 10% of 
the inhaled drug powder reaches the alveoli (2). In addition, many current and emerging 
formulations would benefit from improved drug dissolution rate, which often enhances drug 
bioavailability.
In recent years, significant effort has been dedicated to expand nanotechnology for drug 
delivery since it offers a potential means of improving the delivery of small molecule drugs, 
as well as macromolecules such as proteins, peptides or genes to the tissue of interest (5). 
The increase in the percentage of poorly water-soluble molecules being identified as active 
pharmaceutical ingredients beckons new approaches to bring these molecules to the market 
place in a timely fashion (6). Nanoparticles, whether amorphous or crystalline, offer an 
interesting way of formulating drugs having poor water solubility (7). By presenting drugs at 
the nanoscale, dissolution can be rapid and as a result the bioavailability of poorly soluble 
drugs can be significantly improved (8, 9). Nanoparticles have been disregarded to some 
extent in dry powder dosage forms because particles < 1 μm have a high probability of being 
exhaled before deposition, are prone to particle growth due to Ostwald ripening and can 
suffer from uncontrolled agglomeration (4, 10–12). Conversely, particles exhibiting an 
aerodynamic diameter from 1 to 5 μm are more likely to bypass the mouth and throat, 
resulting in augmented deposition in the lung periphery (11, 13).
Budesonide is a potent nonhalogenated corticosteroid with high glucocorticoid receptor 
affinity, airway selectivity and prolonged tissue retention. It inhibits inflammatory 
symptoms, such as edema and vascular hyperpermeability (14). Budesonide is already 
applied through dry powder inhalers (DPI, Pulmicort), metered dose inhalers (pMDI, 
Rhinocort) or ileal-release capsules (Entocort) (15). This drug is considered one of the most 
valuable therapeutic agents for the prophylactic treatment of asthma despite its poor 
solubility in water (21.5 μg/ml under constant agitation) (16).
The objective of this study was to translate budesonide nanosuspensions into dry powder 
formulations capable of effective deposition and rapid dissolution. Different surfactants 
were used to create surface charge on the nanoparticles and charge interactions were 
leveraged to flocculate nanoparticles into nanoparticle agglomerates exhibiting a particle 
size range of ~2–4 μm. Nanoparticle suspensions were evaluated by measuring particle size, 
polydispersity and zeta potential. Nanosuspensions were then flocculated and lyophilized to 
obtain dry powders composed of micron-sized agglomerates. Nanoparticle agglomerates 
were characterized by the determination of particle size, aerolization efficiencies, flowability 
characteristics, process yield and loading efficiency. Finally, dissolution studies were 
performed for the selected nanoparticles and nanoparticle agglomerates, which were 
compared with the stock drug. The present work represents an approach to harmonize the 
features of micro- and nanostructure for developing novel dry powder aerosols.
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2. Materials and methods
2.1. Materials
Budesonide (Bud), L-α-phosphatidylcholine (lecithin; Lec), cetyl alcohol (CA), L-leucine 
(Leu), polyvinylpyrrolidone (PVP), sorbitan tri-oleate (Span 85) and sodium chloride were 
purchased from Sigma Chemicals Co, USA. Pluronic F-127 (PL, Mw ~12,220) was 
purchased from BASF, The Chemical Company, USA. Polyvinyl alcohol (PVA; Mw = 
22,000, 88% hydrolyzed) was purchased from Acros Organics, New Jersey, USA. 
Potassium dihydrogen phosphate, disodium hydrogen phosphate, acetone, ethanol and 
acetonitrile were purchased through Fisher Scientic. Floatable dialysis membrane units (Mw 
cut-off = 10,000 Da) were obtained from Spectrum Laboratories Inc., USA. A549 cells were 
obtained from the American Type Culture Collection (ATCC, Rockville, MD). The cell 
culture medium (Ham’s F-12 Nutrient Mixture, Kaighn’s modified with L-glutamine) was 
purchased through Fisher Scientic. Fetal bovine serum (FBS) was purchased from Hyclone. 
Penicillin-streptomycin was purchased from MB Biomedical, LLC. Trypsin- EDTA was 
purchased through Gibco. MTS reagent [tetrazolium compound; 3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] was 
purchased from Promega, USA. Double-distilled water was used throughout the study, 
provided by an EASYpure® RODI (Barnstead International, Model # D13321).
2.2. Preparation of budesonide nanosuspensions
Nanosuspensions were prepared using a precipitation technique. Briefly, solutions of 
budesonide in acetone were prepared at concentrations of 0.1 and 0.2% w/v and water was 
used as nonsolvent. To precipitate the drug, the solution of budesonide was directly injected 
into the non-solvent at a rate of 1 mL/min under sonication (Fisher Scientic, Sonic 
Dismembrator) with an amplitude of 46% in an ice bath. The selected surfactants for the 
study included hydrophobic (cetyl alcohol and Span 85), hydrophilic (PL, PVA and PVP) 
and amphoteric (lecithin). The hydrophobic and amphoteric surfactants were added to the 
drug organic solvent solution and the contents were allowed to stand at room temperature 
for 30 to 45 minutes with occasional vortexing to allow complete solubilization of the drug 
and the surfactants. Hydrophilic surfactants were added to the aqueous phase. Surfactants 
were used individually or in combination as reported.
2.3. Flocculation of budesonide nanoparticles
The budesonide nanoparticle agglomerates were prepared by slow addition of L-leucine 
solution (1 % w/v) in water to flocculate nanoparticle suspensions during homogenization at 
25,000 rpm for 30 sec. The amount of L-leucine added was adjusted to a drug:leucine ratio 
equal to 1:1. The size of budesonide nanoparticle agglomerates was measured in Isoton 
diluent using a Coulter Multisizer 3 (Beckman Coulter Inc.) equipped with a 100 μm 
aperture after three hours of incubation with the flocculating agent. The flocculated 
suspensions were kept overnight at room temperature to allow evaporation of acetone and 
then frozen at −80° C and transferred to a freeze dryer (Labconco, FreeZone 1). Drying 
lasted for 36 hours to remove all appreciable water content. Lyophilized powder was stored 
at room temperature for further characterization
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2.4. Characterization of the prepared nanoparticles and nanoparticle agglomerates
2.4.1. Particle size analysis and Zeta potential measurement of the selected 
nanosuspensions—The size and zeta potential of the nanosuspensions were determined 
by dynamic light scattering (Brookhaven, ZetaPALS). Zeta potential measurements were 
performed using 1 mM KCl solution. All measurements were performed in triplicate.
2.4.2. Determination of particle size distribution and aerodynamic diameter of 
the prepared nanoparticle agglomerates—The particle size of the dispersed 
nanoparticle agglomerates as well as the resuspended lyophilized powder was measured 
using a Coulter Multisizer 3. The aerodynamic size distributions of the agglomerate powders 
were measured directly from lyophilized powder by time-of-flight measurement using an 
Aerosizer LD (Amherst Instruments) equipped with a 700 μm aperture operating at 6 psi.
2.4.3. Aerosolization of nanoparticle agglomerates—Aerodynamic characteristics 
of selected nanoparticle agglomerates were studied in vitro using a Tisch Ambient Cascade 
Impactor (Tisch Environmental, Inc., Ohio). The study was carried out by applying ~20 mg 
powder manually into the orifice of the instrument at three air flow rates; ~15 L/min, ~30 
L/min and ~60 L/min. Cut-off particle aerodynamic diameters at 30 L/min for each stage of 
the impactor were: pre-separator (10.00 μm), stage 0 (9.00 μm), stage 1 (5.8 μm), stage 2 
(4.7 μm), stage 3 (3.3 μm), stage 4 (2.1 μm), stage 5 (1.1 μm), stage 6 (0.7 μm), stage 7 (0.4 
μm) and filter (0 μm). Nanoparticle agglomerates deposited on each stage of the impactor 
were determined by measuring the difference in weight of filters placed on the stages. The 
mass median aerodynamic diameter, MMAD, and geometric standard deviation, GSD, were 
obtained by a linear fit of the cumulative percent less-than the particle size range by weight 
plotted on a probability scale as a function of the logarithm of the effective cut-off diameter 
(17, 18).
2.4.4. Transmission electron microscopy (TEM)—Image data was used to 
corroborate the size of nanoparticles and nanoparticle agglomerates and to observe their 
morphological aspects. Transmission electron micrographs (TEM) were obtained for 
budesonide nanoparticles and nanoparticle agglomerates using a JEOL 1200 EXII 
transmission electron microscope. Initially, carbon-coated grids (Electron Microscopy 
Sciences) were floated on a droplet of the suspensions on a flexible plastic film (Parafilm), 
to permit the adsorption of the particles onto the grid. After this, the grid was blotted with a 
filter paper and air dried for 1 hr.
2.4.5. SSNMR analysis—All 13C spectra were collected using a Chemagnetics CMX-300 
spectrometer using ramped amplitude cross-polarization (RAMP) (19), magic-angle 
spinning (MAS) (20), and SPINAL-64 decoupling (21). Samples were packed in 7 mm 
zirconia rotors using Teflon® end caps, and spun at 4 kHz in a 7 mm spin module from 
Revolution NMR.
All spectra are the sum of 2,000–48,000 transients collected using a 1–1.5 s pulse delay, a 
contact time of 0.5–2 ms, and a 1H 90° pulse width of 3–4.5 μs. The free induction decays 
consisted of 512–2048 points with a dwell time of 33.3 μs. The spectra were externally 
El-Gendy et al. Page 4













referenced to tetramethylsilane using the methyl peak of 3-methylglutaric acid at 18.84 ppm 
(22).
The assignment of the peaks in the 13C spectrum of the “as received” budesonide was 
performed using the modified spectral editing methods of Hu et al. (23) and the 13C solution 
predictions from ChemBioDraw Ultra (version 11.0) from CambridgeSoft and ACD/CNMR 
Predictor (version 7.09) from ACD/Labs. The spectral editing subspectra were collected 
using the parameters given in Table I. These parameters were optimized using 3-
methylglutaric acid.
2.4.6. Determination of process yield—The lyophilized powder for the prepared 
nanoparticle agglomerates was weighed and the yield was calculated using the following 
expression:
2.4.7. Budesonide loading efficiency measurement—Budesonide loading 
efficiency was assessed by dispersing one mg of the lyophilized powder in 10 mL ethanol. 
The dispersion was sonicated in a bath-type sonicator (Branson 3510) for 2 hours and then 
kept overnight at room temperature to allow complete dissolution of the drug by ethanol. 
Then the solution was centrifuged (Beckman, Avanti ™) at ~15,000 rpm for 30 min to 
remove insoluble surfactants and L-leucine and the amount of drug in the supernatant was 
determined spectrophotometrically (Agilent C) at 243 nm. Drug loading was defined as 
follows:
2.4.8. Flowability characteristics—The flow properties of the nanoparticle 
agglomerates were assessed by angle of repose (tan θ = height/radius) measurement of the 
dried powders (24). The fixed- height cone method was used. A glass funnel with cut stem 
surface of 5 mm internal diameter was fixed at 2.5 cm height over a flat surface. The 
powders were allowed to flow gently through the funnel until a cone was formed and 
reached the funnel orifice. The flow of powder was then stopped and the average diameter 
of the formed cone (D) was measured. The area of the base of the cone was taken as a 
measure of the internal friction between the particles. The angle of repose was calculated by 
the equation: tan θ = height/radius.
In addition, the bulk density, Hausner ratio (Tapped density/bulk density) and Carr’s index 
(Ci) [(Tapped density − bulk density)/ Tapped density X 100%] were also determined for the 
dried powders (24, 25). Five mg of powders were weighed and poured into a 10 mL 
graduated measuring cylinder. The bulk volume occupied (Vb) was recorded. The measuring 
cylinder was tapped until a constant value was obtained and the tapped volume was recorded 
(Vt). The process was repeated at least three times and the average was taken in each case. 
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The bulk and tapped densities of powder were calculated by dividing the weight by the 
corresponding bulk volume or tapped volume recorded.
2.5. Dissolution studies
The dissolution of the prepared nanoparticles and nanoparticle agglomerates was determined 
and compared with the dissolution characteristics of the stock drug. The dissolution of 
budesonide was carried out at 37 ± 0.5°C in a 400 mL beaker. A known amount (~10 mg) of 
the lyophilized powder was suspended in 10 mL phosphate buffered saline (PBS, pH 7.4) 
and was placed into a floatable dialysis membrane unit (Mw cut-off = 10,000 Da), and the 
unit was allowed to float in a beaker containing 300 mL of PBS. The solution was stirred at 
a constant speed (100 rpm) using a magnetic stirrer (Barnstead, Thermolyne MIRAK™). At 
predetermined time intervals for a total period of 8 hours, aliquots (5 ml) of the medium 
were removed and fresh medium was immediately added to continue the dissolution study. 
Studies were conducted in triplicate. The budesonide concentration was analyzed using a 
reverse-phase HPLC method. A Shimadzu HPLC system including a solvent delivery pump 
(Shimadzu LC-10AT), a controller (Shimadzu SCL-10A), an autoinjector (Shimadzu 
SIL-10AxL), and a UV detector (Shimadzu SPD-10A) was used in this study. The peak 
areas were integrated using Shimadzo Class VP (Version 4.3). A 4.6 mm × 100 mm long 
Zorbax SB C-18 column (Agilent C) with a particle diameter of 3.5 μm was used. During 
the assay, budesonide was eluted isocratically at a mobile phase flow rate of 0.6 mL/minute 
and monitored with a UV detector operating at 254 nm. The mobile phase for the assay 
consisted of an acetonitrile and water mixture (45:55 v/v) (2). The run time for the assay was 
20 minutes, and the retention time for budesonide was 14.01 minutes.
2.6. Cytotoxicity assay
The cytotoxicity of selected nanoparticles and nanoparticle agglomerates was assessed using 
the CellTiter 96® Aqueous Cell Proliferation Assay (Promega) and compared with stock 
budesonide, lecithin, leucine, physical mixtures of these ingredients and blank nanoparticle 
agglomerates. In this experiment, 8 × 104 A549 cells/well were seeded in 96-well microtiter 
plates. At the end of the incubation period (12 h), 20 μl of MTS reagent solution was added 
to each well and incubated for 3 h at 37 °C. The absorbance was measured at 490 nm using a 
microtiter plate reader (SpectraMax, M25, Molecular Devices Corp., CA). The percentage 
of viable cells with all tested concentrations was calculated relative to untreated cells (26, 
27).
3. Results and discussion
3.1. Fabrication of budesonide nanoparticles
Various methods have been reported for generating nanoparticles of poorly water soluble 
drugs (8, 28, 29). A precipitation method was selected to produce budesonide nanoparticles. 
Different concentrations of the drug and various types and ratios of surfactants, individually 
or in combination, were evaluated as a means to control the particle size and surface charge. 
Surfactants were chosen from excipients regarded as suitable for inhalation that have been 
designated as safe for human use (3). Formulations prepared using PVP and PVA in 
different ratios produced very large particle sizes even when combined with other 
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surfactants. The mean particle size of formulations containing lecithin, cetyl alcohol, Span 
85 and/or PL ranged from ~130 to 323 nm. Formulations containing Span 85 alone or in 
combination with lecithin yielded the smallest particle size but since Span is liquid at room 
temperature, it was not suitable for use in dry powder formulations.
Attempts to generate budesonide nanoparticles using PL alone or in combination with 
lecithin yielded reasonable particle sizes (~129–270 nm) but offered very low nanoparticle 
yields and high polydispersity values (30). Selected surfactant combinations for preparing 
budesonide nanosuspensions in acetone were designated F1 (0.1% w/v Bud + 0.02% w/v 
Lec), F2 (0.1% w/v Bud + 0.02% w/v CA + 0.01% w/v PL) and F3 (0.2% w/v Bud + 0.04% 
w/v CA + 0.02% w/v PL) as reported in Table II. These surfactant combinations 
demonstrated small particle size and could be used in dry powder formulations. A small 
change in zeta potential was observed with different types of surfactants and the values 
ranged from 22.5–25.1 mV (Table III). The charged surface of the nanoparticles provided 
the potential for destabilizing this colloid via interaction with a flocculating agent to form 
nanoparticle agglomerates.
3.2. Agglomerated budesonide nanoparticles yielded desirable aerosol characteristics
The mechanism to control nanoparticle agglomeration is mainly driven by leveraging the 
competitive processes of attraction (van der Waals force) and repulsion (electrostatic 
repulsive force or steric hindrance barrier or both). If particles are mainly stabilized 
electrostatically, disruption of the electrostatic double layer surrounding the particles will 
result in the agglomeration of nanoparticles (31). The addition of flocculating agents has 
also been speculated to decreases the cohesion between particles. It is thought that these 
agents may interfere with weak bonding forces between small particles, such as Van der 
Waals and Coulomb forces. These agents may act as weak links or “chain breakers” between 
the particles which are susceptible to disruption in the turbulent airstream created during 
inhalation (3, 32). The amino acid, L-leucine, used as a flocculating agent in these studies 
may also act as an anti-adherent material to yield a high respirable fraction of the 
agglomerated budesonide nanoparticles (33).
Flocculation of nanoparticles resulted in the formation of agglomerates within the 
micrometer or sub-micrometer scale consisting of closely-packed nanoparticles (34). 
Nanoparticle agglomerates were prepared through the slow incorporation of a flocculating 
agent (L-leucine) during homogenization (25,000 rpm) for 30 sec. The geometric size 
distribution of the prepared nanoparticle agglomerates was measured in Isoton diluent using 
a Coulter Multisizer 3. The size average of the three selected nanoparticle agglomerate 
formulations ranged from ~2–4 μm (Table IV). The size distributions of resuspended 
lyophilized powders were slightly broader and the average particle size was slightly 
increased, when compared to the nanoparticle agglomerates prior to lyophilization (Table IV 
and Fig. 1). This may be due to the deposition of nanoparticles on agglomerates during 
lyophilization or to cohesion between agglomerates as a result of drying. The key physical 
parameter that predicts the site of aerosol deposition within the lungs for particles larger 
than several hundred nanometers is the aerodynamic diameter (daero) (35). The aerodynamic 
diameter of the flocculated nanoparticles, measured by an Aerosizer LD, was smaller than 
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the geometric diameter and the aerodynamic size distribution was narrower than the 
geometric size distribution (Table IV and Fig. 2). When compared to the geometric 
diameter, the lower aerodynamic diameter was likely due to the low density of nanoparticle 
agglomerates.
The theoretical mass–mean aerodynamic diameters (daero) of the nanoparticle agglomerates, 
determined from the geometric particle size and tapped density, was found to be 2, 2.1 and 
2.5 μm for F1, F2 and F3, respectively as calculated from the relationship (36):
Where dgeo = geometric diameter, γ = shape factor (for a spherical particle, γ = 1; for 
aerodynamic diameter calculations, the particles in this study were assumed to be spherical), 
ρ = particle bulk density and ρa = water mass density (1 g/cm3). Tapped density 
measurements underestimate particle bulk densities since the volume of particles measured 
includes the interstitial space between the particles. The true particle density, and therefore 
the aerodynamic diameter of a given powder, is expected to be slightly larger than reported 
(37). Particles with a daero between 1 and 5 μm that are inhaled via the mouth are capable of 
efficient alveolar deposition, whereas daero between 4 and 10 μm are more likely to deposit 
primarily in the tracheobronchial region of the lungs (35). Therefore, the budesonide 
nanoparticle agglomerates with daero in the 2–2.5 μm range are expected to deposit primarily 
in the alveolar region of the lungs.
Aerosizer results and theoretical MMAD calculations were corroborated by cascade 
impaction studies at air flow rates of ~15 L/min, ~30 L/min and ~60 L/min (Fig. 3). At these 
flow rates, most nanoparticle agglomerates were deposited in stages 6 and 7 of the cascade 
impactor which was suggestive of efficient aerosolization and a high fine particle fraction. 
The aerosolization efficiency of nanoparticle agglomerates was represented by the percent 
emitted fraction (%EF), percent respirable fraction (RF), mass-median aerodynamic 
diameter (MMAD) and geometrical standard deviation (GSD). The percent emitted fraction 
was determined from the following equation:
The high emitted fraction of nanoparticle agglomerates obtained at the tested flow rates 
suggested efficient aerosolization of the powder (Table V). The percent respirable fraction 
(RF), referred to also as the fine particle fraction of the total dose (FPFTD), was calculated as 
the percentage of aerosolized particles that reached the lower seven stages of the impactor 
(corresponding to aerodynamic diameters below 5.8 μm), or the lower five stages 
(corresponding to aerodynamic diameters below 3.3 μm) according to the following 
equation (17, 37):
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The results of the respirable fraction also suggested the efficient aerosolization of 
nanoparticle agglomerate powders (Table V) (38). The geometric standard deviation (GSD) 
of the nanoparticle agglomerates was determined from the following equation (35):
Where dn is the diameter at the nth percentile of the cumulative distribution. The mass–mean 
geometric size of nanoparticle agglomerates ranged between 3 and 4 μm with a GSD of ~2.3 
μm (Table V). Typical GSD values for aerosol particles are between 1.3–3.0 (17). The mass-
mean aerodynamic diameter (MMAD) of the selected nanoparticle agglomerates, as 
calculated from the cascade impaction results (Table V) was close to that obtained from the 
Aerosizer (Table IV) although it was slightly smaller than the theoretical density values 
calculated from the tapped density indicating the suitability of the prepared nanoparticle 
agglomerate powders for peripheral lung deposition (i.e., < 3 μm).
Electron microscopy was used to study the morphology of budesobide nanoparticle and 
nanoparticle agglomerate formulations. Transmission electron micrographs (TEM) of F1 
nanoparticles (Fig. 4A) depicted slightly elongated nanoparticles with smooth surfaces and a 
particle size around 170 nm. TEM images of F1 nanoparticle agglomerates (Fig. 4B) show 
that the nanoparticles were flocculated into micron sized agglomerates with irregular 
structure and some sharp edges.
Fig. 5. shows the 13C spectra of budesonide by itself and in formulations. Both the 
budesonide as received and the leucine exhibit relatively narrow lines (several tens of hertz), 
indicating that these samples are crystalline. Lecithin also had narrow lines, which is 
consistent with it being a crystalline form of phosphatidylcholine; however, it is a semi-solid 
and therefore cannot be crystalline. Conversely the budesonide that was melt quenched had 
significantly broader lines (several hundreds of hertz) indicating that the budesonide is 
consistent with it being amorphous. In the nanoparticles, the peaks for budesonide are 
similar to the peaks in the budesonide that was melt quenched, although the peak at ~180 
ppm shows that there is a small amount of crystalline budesonide in the nanoparticles. The 
tall, sharp peaks in the spectrum of the nanoparticle agglomerates align with the peaks in the 
leucine spectrum and showed that the leucine in the formulation has undergone phase 
separation and has crystallized to some extent. The peak at 180 ppm showed that the amount 
of crystalline budesonide had increased in the formulation of the nanoparticle agglomerates. 
This was consistent with the shape of several other budesonide peaks in the spectrum.
Budesonide consists of 25 carbons (Fig. 6); however, the spectrum of the budesonide as 
received had at least 27 resolved peaks and several peaks that may be the result of several 
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overlapping peaks. The extra peaks did not seem to be due to splitting, as would be expected 
if there were more than one molecule in the asymmetric unit cell.
The budesonide is a racemic mixture of both epimers that have been shown to pack 
differently in the crystal lattice (39). Therefore, spectral editing was used in an attempt to 
assign the peaks in the spectrum to determine if the differences in the two epimers could be 
used to explain the “extra” peaks. The spectral editing experiment allowed the assignment of 
carbon type (C, CH, CH2, or CH3) to a peak, these assignments could then be combined 
with predictions to assign the peaks to specific carbons within the molecule. The carbon type 
of most of the peaks could be assigned from these experiments (Fig. 7) with the exception of 
a few of the aliphatic peaks (particularly ~30–40 ppm). These results were then compared 
with predictions of the solution state chemical shifts from two different software programs 
and the resulting assignments are shown in Table VI. Chemical shifts for a compound in the 
solution and solid state can vary by as much as 10 ppm. For this reason, some assignments 
can be narrowed down to a few possibilities but an exact assignment was not possible with 
this data. For example, carbons 2 and 4 can be assigned to the peaks at 122.5 and 128.2, but 
it was not possible to definitively determine which carbon was associated with which peak. 
The solution predictions placed carbon 22 at ~103 ppm, while the spectral editing 
experiment showed that there are two peaks at 104.5 and 107.3 ppm that can be assigned to 
CH carbons. Additionally, carbon 22 is the chiral center of the epimers. Based on these 
observations and the fact that the two epimers have been shown to pack in different 
conformations, both peaks were assigned to carbon 22 with the interpretation that each peak 
represents one of the epimers. It is important to note that this interpretation assumes the 
budesonide is pure, which we have not confirmed. Additionally, there is always the 
possibility that these are different polymorphs; however, reports of polymorphism in 
budesonide have not been identified.
The process of agglomerating nanoparticles was evaluated to determine their yield. The 
results (Table IV) have shown that the process was efficient providing a high yield (~90–
95%) and minimum batch variability. The loading efficiency of the drug in the prepared 
nanoparticle agglomerates was found to be between 85–95% (Table IV), thus demonstrating 
minimal loss of drug during formation.
The flow characteristics of the selected nanoparticle agglomerates were also determined 
(Table VII). Angle of repose, Hausner ratio and Carr’s index are considered to be indirect 
methods for quantifying powder flowability (24). Budesonide nanoparticle agglomerates 
generally exhibited similar bulk densities and lower tapped densities than that of the stock 
drug powder. Nanoparticle agglomerates also demonstrated improved flow properties. This 
may be attributed to the reduced denisity of the nanoparticle agglomerates. In addition, L-
leucine has been reported to reduce surface energy in dry powders and may improve 
flowability in this case (40). Formula F3 showed slightly better flowability compared to the 
others according to the Carr’s index; however, all nanoparticle agglomerate powders 
possessed acceptable flowability.
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3.3. Budesonide nanoparticle and nanoparticle agglomerates showed improved 
dissolution rates
A dissolution study of budesonide was conducted for the prepared nanoparticles and 
nanoparticle agglomerates and compared to the unprocessed drug. The cumulative 
percentage of drug dissolved after 8 hours (Q8h) was found to be slower than that of the 
nanoparticles and faster than that of the stock budesonide (Table IV). This finding was the 
expected result of increasing the surface area by decreasing the particle size. F2 and F3 
nanoparticle and nanoparticle agglomerate formulations showed faster drug dissolution than 
F1 which may be due to the incorporation of the hydrophilic surfactant, PL (Fig. 8). In 
addition, increasing the concentration of this surfactant (F3) led to even faster dissolution. 
Linear regression analysis of the dissolution data concluded that the drug was released by 
the Higuchi diffusion mechanism in all cases. A two-way Analysis of Variance (ANOVA) 
was performed to determine the significance of differences in dissolution kinetics. 
Significant differences (α = 0.05) existed between nanoparticles, nanoparticle agglomerates 
and stock budesonide. No significant differences existed between different nanoparticles or 
nanoparticle agglomerate formulations. A significant improvement (P<0.05) in the 
dissolution behavior of the nanoparticles and nanoparticle agglomerates was also observed 
when these were individually compared to the stock budesonide.
3.4. Formulation components exhibited minimal cytotoxicity
The cytotoxicity of the different budesonide formulations were compared to stock 
budesonide, lecithin, leucine, physical mixtures of F1 components and blank F1 nanoparticle 
agglomerates (Fig. 9). Stock budesonide, excipients and physical mixtures of F1 
components up to 5 mg/mL did not show any significant cytotoxicity in A549 cells at the 
end of 12 hours. Blank F1 nanoparticle agglomerates did induce a very low level of 
cytotoxicity where the IC50 was found to be 0.97 mg/mL. Additionally, F1 nanoparticles and 
nanoparticle agglomerates also induced very low level of cytotoxicity with IC50 values equal 
to 1.67 mg/mL and 1.91 mg/mL, respectively. The IC50 values occurred at higher 
concentrations than the maximum daily dose of inhaled budesonide currently prescribed. 
These results may suggest that lecithin was responsible for the cytotoxic effect.
4. Conclusion
Many current techniques to generate dry powder aerosols have a major disadvantage of poor 
control over the particle shape, size and size distribution. In addition, many pulmonary 
formulations may benefit from the improved bioavailability and rapid onset of action that 
may be achieved by using drug nanoparticles. In this work, budesonide nanosuspensions 
were successfully prepared yielding nanoparticles in the range of ~160–230 nm. This was 
accomplished by using surfactants proven to be safe for human use such as lecithin. 
Nanosuspensions were flocculated using L-leucine and the resulting nanoparticle 
agglomerates were analyzed. Nanoparticle agglomerates were efficiently aerosolized and 
offered a high fine particle fraction suitable for accessing the peripheral lung. Nanoparticle 
agglomerates also exhibited significantly faster budesonide dissolution when compared to 
the stock powder. In conclusion, budesonide nanoparticle agglomerates demonstrated a 
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desirable microstructure for efficient lung deposition and nanostructure for rapid dissolution 
of poorly water soluble drugs.
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The particle size distributions of budesonide nanoparticle agglomerates in suspension after 
flocculation and resuspended after lyophilization.
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Aerodynamic size distributions of budesonide nanoparticle agglomerates after 
lyophilization.
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The distribution of budesonide nanoparticle agglomerate formulations (A) F1, (B) F2, and 
(C) F3 deposited on the stages of a cascade impactor. (D) Formulations were compared with 
stock budesonide at a flow rate of ~30 L/min.
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Transmission electron micrographs of A) F1 nanoparticles and B) F1 nanoparticle 
agglomerates.
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13C CP/MAS spectra of budesonide, excipients, and budesonide formulations. The 
nanoflocs spectrum was expanded 8 times vertically to produce the nanoflocs x8 spectrum to 
aid the interpretation of the budesonide peaks.
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Structure of budesonide with carbon numbering.
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13C CP/MAS spectra from spectral editing experiment.
All = all carbon types are shown, C+CH3 = only unprotonated and methyl carbons are 
shown, C = only unprotonated carbons are shown, CH = only methine carbons are shown, 
and CH2 = only methylene carbons are shown.
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In-vitro dissolution profiles of budesonide in PBS (pH 7.4) from budesonide stock, 
nanoparticle formulations (NP) and nanoparticle agglomerate formulations (NA).
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Viability of A549 cells in the presence of formulation components as determined by an MTS 
assay.
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Table II
Composition of the selected formulations.
Formulation Budesonide (% w/v) Lecithin (% w/v) Cetyl alcohol (% w/v) Pluronic F127 (% w/v)
F1 0.1 0.02
F2 0.1 0.02 0.01
F3 0.2 0.04 0.02
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Table III
Physical properties of budesonide nanoparticle (values = average ± S.D.).
Formulation Nanoparticle size (nm) Zeta-potential (mV) Polydispersity
F1a 160.9 ± 15.6 25.1 ± 1.3 0.41 ± 0.1
F2b 188.8 ± 26.3 24.2 ± 1.1 0.34 ± 0.02
F3c 232.2 ± 11.2 22.5 ± 0.5 0.33 ± 0.02
a
F1 = 0.1: 0.02; Bud: Lec
b
F2 = 0.1: 0.02: 0.01; Bud: CA: PL
c
F3 = 0.2: 0.04: 0.02; Bud: CA: PL
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Table IV
Characteristics of budesonide nanoparticle agglomerates (values = average ± S.D.).
Characteristics Formulations
F1a F2b F3c
Geometric particle size (μm) of NAd before lyophilization 2.8 ± 0.4 2.7 ± 0.4 3.2 ± 0.7
Geometric particle size (μm) of lyophilized NAd 3.1 ± 0.6 3.3 ± 0.7 3.9 ± 1.1
MMADf of lyophilized NAd 1.4 ± 1.7 2.1 ± 1.8 1.9 ± 1.8
% Process yield of lyophilized NAd 95.5 ± 4.9 92.7 ± 3.1 89.7 ± 3.6
Loading Efficiency of lyophilized NAd 95.9 ± 3.6 86.5 ± 6.0 92.5 ± 6.6
Q8hg NPe 61.5 % ± 1.6 75.5 % ± 9.9 88.9 % ± 3.0
Q8hg NAd 41.8 % ± 4.6 51.2 % ± 5.1 63.1 % ± 5.1
a
F1 = 0.1: 0.02; Bud: Lec
b
F2 = 0.1: 0.02: 0.01; Bud: CA: PL
c






MMAD: Mass median aerodynamic diameter obtained from Aerosizer.
g
Q8h: % budesonide dissolved after 8 hours.
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Table VI
13C peak assignments for budesonide as received.
Assignment As Received ACD/Labs* ChemBioDraw*
20 209.0 207.0 211.2
3 185.4 186.2 185.7
5 170.6 170.3 168.1





22 104.5 and 107.3** 105.1 102.0
17 99.8 94.4 105.0




















8 31.6 32.3 34.6
19




24 17.2 18.4 13.1
*
Software predictions of chemical shifts in solution.
**
See text for explanation.
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